Free Trial
NASDAQ:VOR

Vor Biopharma 11/7/2024 Earnings Results & Report

Vor Biopharma logo
$19.42 0.00 (0.00%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$19.11 -0.31 (-1.60%)
As of 05:54 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Vor Biopharma met analyst earnings expectations in results released November 7, 2024. The company reported EPS of -$8.00 versus the -$8.00 consensus estimate.

Earnings Announcement Details

Report Date
Time
After Market Closes

Vor Biopharma EPS Results

Actual EPS
-$8.00
Consensus EPS
-$8.00
Beat/Miss
Met Expectations
One Year Ago EPS
N/A
EPS Beat Rate
1 of last 8 quarters

Vor Biopharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Vor Biopharma Earnings FAQ

Vor Biopharma (NASDAQ:VOR) reported earnings of -$8.00 per share for the quarter, matching the consensus estimate of -$8.00. The report was announced on Thursday, November 7, 2024.

Vor Biopharma Earnings Headlines

My public warning after 55 years of watching the markets
Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.tc pixel
HC Wainwright Forecasts Stronger Earnings for Vor Biopharma
See More Vor Biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Vor Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vor Biopharma and other key companies, straight to your email.

About Vor Biopharma

Vor Biopharma (NASDAQ:VOR) is a clinical-stage biotechnology company focused on developing cell therapies for blood cancers. The company combines gene editing of blood stem cells with engineered immune-cell therapies, with the goal of enabling targeted treatment while protecting healthy blood-forming cells.

Its research has included trem-cel, an investigational gene-edited stem cell therapy designed to remove the CD33 protein from transplanted cells, and VCAR33, an investigational CAR T-cell therapy targeting CD33. These programs have been developed primarily for acute myeloid leukemia (AML); neither is an approved treatment.

Founded in 2015 and based in Cambridge, Massachusetts, Vor has focused its clinical development and research on cancer therapies. Its work has been centered on the U.S. biotechnology and clinical-research landscape.

View Vor Biopharma Profile